These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 27587951)

  • 1. A Comparison of Substantia Nigra T1 Hyperintensity in Parkinson's Disease Dementia, Alzheimer's Disease and Age-Matched Controls: Volumetric Analysis of Neuromelanin Imaging.
    Moon WJ; Park JY; Yun WS; Jeon JY; Moon YS; Kim H; Kwak KC; Lee JM; Han SH
    Korean J Radiol; 2016; 17(5):633-40. PubMed ID: 27587951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substantia nigra neuromelanin magnetic resonance imaging in de novo Parkinson's disease patients.
    Reimão S; Pita Lobo P; Neutel D; Correia Guedes L; Coelho M; Rosa MM; Ferreira J; Abreu D; Gonçalves N; Morgado C; Nunes RG; Campos J; Ferreira JJ
    Eur J Neurol; 2015 Mar; 22(3):540-6. PubMed ID: 25534480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T1-weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson's disease.
    Schwarz ST; Rittman T; Gontu V; Morgan PS; Bajaj N; Auer DP
    Mov Disord; 2011 Aug; 26(9):1633-8. PubMed ID: 21491489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Magnetic resonance correlation of iron content with neuromelanin in the substantia nigra of early-stage Parkinson's disease.
    Reimão S; Ferreira S; Nunes RG; Pita Lobo P; Neutel D; Abreu D; Gonçalves N; Campos J; Ferreira JJ
    Eur J Neurol; 2016 Feb; 23(2):368-74. PubMed ID: 26518135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Study of MRI Biomarkers in the Substantia Nigra to Discriminate Idiopathic Parkinson Disease.
    Pyatigorskaya N; Magnin B; Mongin M; Yahia-Cherif L; Valabregue R; Arnaldi D; Ewenczyk C; Poupon C; Vidailhet M; Lehéricy S
    AJNR Am J Neuroradiol; 2018 Aug; 39(8):1460-1467. PubMed ID: 29954816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Substantia Nigra Neuromelanin as an Imaging Biomarker of Disease Progression in Parkinson's Disease.
    Fabbri M; Reimão S; Carvalho M; Nunes RG; Abreu D; Guedes LC; Bouça R; Lobo PP; Godinho C; Coelho M; Gonçalves NC; Rosa MM; Antonini A; Ferreira JJ
    J Parkinsons Dis; 2017; 7(3):491-501. PubMed ID: 28671143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative Analysis Versus Visual Assessment of Neuromelanin MR Imaging for the Diagnosis of Parkinson's disease.
    Reimão S; Pita Lobo P; Neutel D; Guedes LC; Coelho M; Rosa MM; Ferreira J; Abreu D; Gonçalves N; Morgado C; Nunes RG; Campos J; Ferreira JJ
    J Parkinsons Dis; 2015; 5(3):561-7. PubMed ID: 26406136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spatiotemporal changes in substantia nigra neuromelanin content in Parkinson's disease.
    Biondetti E; Gaurav R; Yahia-Cherif L; Mangone G; Pyatigorskaya N; Valabrègue R; Ewenczyk C; Hutchison M; François C; Arnulf I; Corvol JC; Vidailhet M; Lehéricy S
    Brain; 2020 Sep; 143(9):2757-2770. PubMed ID: 32856056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Substantia nigra neuromelanin-MR imaging differentiates essential tremor from Parkinson's disease.
    Reimão S; Pita Lobo P; Neutel D; Guedes LC; Coelho M; Rosa MM; Azevedo P; Ferreira J; Abreu D; Gonçalves N; Nunes RG; Campos J; Ferreira JJ
    Mov Disord; 2015 Jun; 30(7):953-9. PubMed ID: 25758364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three-dimensional neuromelanin-sensitive magnetic resonance imaging of the substantia nigra in Parkinson's disease.
    Prasad S; Stezin A; Lenka A; George L; Saini J; Yadav R; Pal PK
    Eur J Neurol; 2018 Apr; 25(4):680-686. PubMed ID: 29341412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A distinct neuromelanin magnetic resonance imaging pattern in parkinsonian multiple system atrophy.
    Simões RM; Castro Caldas A; Grilo J; Correia D; Guerreiro C; Pita Lobo P; Valadas A; Fabbri M; Correia Guedes L; Coelho M; Rosa MM; Ferreira JJ; Reimão S
    BMC Neurol; 2020 Nov; 20(1):432. PubMed ID: 33243166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
    Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
    Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous imaging of locus coeruleus and substantia nigra with a quantitative neuromelanin MRI approach.
    Chen X; Huddleston DE; Langley J; Ahn S; Barnum CJ; Factor SA; Levey AI; Hu X
    Magn Reson Imaging; 2014 Dec; 32(10):1301-6. PubMed ID: 25086330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuromelanin-sensitive magnetic resonance imaging features of the substantia nigra and locus coeruleus in de novo Parkinson's disease and its phenotypes.
    Wang J; Li Y; Huang Z; Wan W; Zhang Y; Wang C; Cheng X; Ye F; Liu K; Fei G; Zeng M; Jin L
    Eur J Neurol; 2018 Jul; 25(7):949-e73. PubMed ID: 29520900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal Changes in Neuromelanin MRI Signal in Parkinson's Disease: A Progression Marker.
    Gaurav R; Yahia-Cherif L; Pyatigorskaya N; Mangone G; Biondetti E; Valabrègue R; Ewenczyk C; Hutchison RM; Cedarbaum JM; Corvol JC; Vidailhet M; Lehéricy S
    Mov Disord; 2021 Jul; 36(7):1592-1602. PubMed ID: 33751655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuromelanin Magnetic Resonance Imaging of the Substantia Nigra in Huntington's Disease.
    Leitão R; Guerreiro C; Nunes RG; Gonçalves N; Galati G; Rosário M; Guedes LC; Ferreira JJ; Reimão S
    J Huntingtons Dis; 2020; 9(2):143-148. PubMed ID: 32065802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging iron and neuromelanin simultaneously using a single 3D gradient echo magnetization transfer sequence: Combining neuromelanin, iron and the nigrosome-1 sign as complementary imaging biomarkers in early stage Parkinson's disease.
    He N; Ghassaban K; Huang P; Jokar M; Wang Y; Cheng Z; Jin Z; Li Y; Sethi SK; He Y; Chen Y; Gharabaghi S; Chen S; Yan F; Haacke EM
    Neuroimage; 2021 Apr; 230():117810. PubMed ID: 33524572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [11C]PIB binding in Parkinson's disease dementia.
    Maetzler W; Reimold M; Liepelt I; Solbach C; Leyhe T; Schweitzer K; Eschweiler GW; Mittelbronn M; Gaenslen A; Uebele M; Reischl G; Gasser T; Machulla HJ; Bares R; Berg D
    Neuroimage; 2008 Feb; 39(3):1027-33. PubMed ID: 18035558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [
    Coakeley S; Cho SS; Koshimori Y; Rusjan P; Ghadery C; Kim J; Lang AE; Houle S; Strafella AP
    Brain Struct Funct; 2018 Mar; 223(2):589-595. PubMed ID: 28884232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between pathology and neuromelanin MR imaging in Parkinson's disease and dementia with Lewy bodies.
    Kitao S; Matsusue E; Fujii S; Miyoshi F; Kaminou T; Kato S; Ito H; Ogawa T
    Neuroradiology; 2013 Aug; 55(8):947-953. PubMed ID: 23673875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.